Supreme Court Of Canada Denies Apotex Leave To Appeal Federal Court Of Appeal's Rejection Of Judicial Review Of Health Canada Decision Regarding India Facilities
Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
As previously reported, the Federal Court of Appeal (FCA) dismissed Apotex's appeal of a judicial review decision of the Therapeutic Products Directorate (TPD) ...
As
previously reported, the Federal Court of Appeal (FCA)
dismissed Apotex's appeal of a judicial review decision of the
Therapeutic Products Directorate (TPD) which required Apotex to
submit additional information concerning products manufactured or
tested in Apotex's facilities in India. The FCA found that the
Federal Court made no reviewable error in its conclusion that the
TPD's decision was not improperly motivated. On February 22,
2019, the Supreme Court dismissed Apotex's application for
leave to appeal (docket No. 38336).
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.